ABT-CIP-10299
Проводит Abbott Medical Devices
Страница компанииSyncAV Post-Market Trial
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT04100148/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 1686 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (06.2026) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 14
Критерии включения
- Scheduled to receive a new CRT implant or an upgrade (Abbott CRT device and Abbott Quadripolar LV lead) from an existing implantable cardioverter defibrillator/pacemaker implant with no more than 10% RV pacing at the last device interrogation, no prior LV lead placement, AND meet the following additional criteria:
- Mild to severe heart failure despite optimal medical therapy for at least 3 months prior to signing consent. Optimal medical therapy is defined as maximal tolerated dose of beta-blockers and a therapeutic dose of angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or aldosterone antagonist
- LVEF ≤ 35% based on a prior standard of care echocardiogram
- Left bundle branch block (LBBB) as documented on an ECG. Criteria for complete LBBB should include,
- i. QRS duration ≥ 120 ms ii. QS or rS pattern in leads V1 iii. mid-QRS notching or slurring in leads I, aVL, V5, and V6 iv. Absence of Q-wave in leads V5 and V6 d. Intact AV conduction (PR interval ≤ 280 ms on surface ECG)
- At least 18 years old, or of legal age and willing and capable to give informed consent specific to each country and national laws
- Willing and able to comply with the prescribed follow-up tests and schedule of evaluations
Критерии невключения
- Recent myocardial infarction or unstable angina within 40 days prior to signing consent
- Recent cardiac revascularization (angioplasty, stent or bypass graft) in the 4 weeks prior to signing consent or planned within 3 months following consent
- Cerebrovascular accident or transient ischemic attack in the 3 months prior to signing consent
- Any other therapeutic cardiovascular procedure (transcatheter aortic valve replacement, MitraClip, cardiac surgery, left atrial appendage closure, patent foramen ovale closure, or any ablation procedures) in the 3 months prior to signing consent
- Permanent or persistent AF at the time of signing consent
- Paroxysmal AF with at least one cardioversion within 60 days prior to signing consent
- Prior CRT device implant
- Prior His Bundle pacing implant or plan to have His Bundle pacing implant
- Pregnant or breastfeeding at the time of signing consent
- Incapacitated or unable to read or write
- Undergone cardiac transplantation or have a classification of Status 1 for cardiac transplantation or consideration for transplantation during the study follow-up period
- Life expectancy < 12 months due to any condition
- Unavailable for at least 12 months of follow-up visits
- Enrolled in or intend to participate in a clinical drug and/or device study during this clinical trial which could confound the results of this trial as determined by Abbott
Источник: ClinicalTrials.gov, NCT04100148 · запись обновлена в реестре 18 декабря 2025.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 3
- Reduction in left ventricular end systolic volume (LVESV) between baseline and 12 months — 12 months following trial randomization
Цель исследования
The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to determine if cardiac resynchronization therapy (CRT) devices programmed with SyncAV ON improve long-term CRT response compared to devices programmed with conventional CRT through evaluation of changes in left ventricular (LV) reverse remodeling.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT04100148 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, сроки, число участников, спонсор, центры
-
Расчёт Клиномира По датам из реестраСтатус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.